Show Notes
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice.
Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University
Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania
More from Lung Cancer Considered
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
Recorded at the 2026 IASLC World Conference on Lung Cancer in Seoul, this special Early Career Takeover episode explores what this annual meeting offers to researchers and clinicians at the start of their careers.
The WHO Eastern Mediterranean Region (EMRO) faces unique challenges around exposures, non-conventional smoking, lung cancer screening, molecular profiling, and evolving therapies in lung cancer. To address this, the inaugural joint IASLC/EMRO workshop took place at the 2026 World Conference on Lung Cancer (WCLC) in Seoul.